A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. (Q51658522)

9 April 2018

title

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. (English)

1 reference

9 April 2018

1 reference

Taff Jones

1

1 reference

9 April 2018

Francine Allard

2

1 reference

9 April 2018

Sonya L Cyr

3

1 reference

9 April 2018

Steven P Tran

4

1 reference

9 April 2018

Martin Plante

5

1 reference

9 April 2018

Joelle Gauthier

6

1 reference

9 April 2018

Nathalie Bellerose

7

1 reference

9 April 2018

George H Lowell

8

1 reference

9 April 2018

David S Burt

9

1 reference

9 April 2018

language of work or name

English

0 references

publication date

1 September 2003

1 reference

9 April 2018

published in

Vaccine

1 reference

9 April 2018

volume

21

1 reference

9 April 2018

issue

25-26

1 reference

9 April 2018

page(s)

3706-3712

1 reference

9 April 2018

Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Immunogenicity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Determinants of immunity to influenza infection in man

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Antibody responses and interferon titers in the respiratory tracts of mice after aerosolized exposure to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Mechanisms of viral clearance and persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900387-6

7 January 2021

10.1016/S0264-410X(03)00387-6

Identifiers

DOI

1 reference

9 April 2018

PubMed ID

12922101

1 reference

9 April 2018